Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.37 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.37 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875857 | 0.87 | PDE4D (0.39) | PDE4DPDE3APOLBALDH1A1LMNA | |
| Azosemide SCHEMBL4421865 | 0.83 | PDE4D (0.70) | PDE4DPDE3APOLBCISD1KCNN1 | |
| Azosemide SCHEMBL48976 | 0.83 | PDE4D (0.70) | PDE4DPDE3APOLBCISD1KCNN1 | |
| Azosemide SCHEMBL30754398 | 0.83 | PDE4D (0.70) | PDE4DPDE3APOLBCISD1KCNN1 | |
| Azosemide SCHEMBL8988688 | 0.82 | PDE4D (0.69) | PDE4DPDE3APOLBCISD1KCNN1 | |
| SCHEMBL11929680 | 0.81 | PDE4D (0.55) | PDE4DPDE3APOLBCISD1KCNN1 | |
| SCHEMBL12391856 | 0.80 | PDE4D (0.44) | PDE4DPDE3APOLBCISD1KCNN1 | |
| SCHEMBL10281116 | 0.80 | PDE4D (0.54) | PDE4DPDE3APOLBCISD1ALDH1A1 | |
| Azosemide SCHEMBL230626 | 0.77 | PDE4D (0.62) | PDE4DPDE3APOLBCISD1ALDH1A1 | |
| SCHEMBL12451382 | 0.75 | POLB (0.40) | PDE4DPDE3APOLBCISD1KCNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8008283-B2 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | AQP4, AVPR2, AQP1 | PDE4D 89/4885PDE3A 125/4885POLB 4721/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | PDE4D 597/4885PDE3A 441/4885POLB 3419/4885 |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | PDE4D 1702/4885PDE3A 1635/4885POLB 4498/4885 |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | SLC1A2, SLC18A2, GRIN2C | PDE4D 1866/4885PDE3A 1938/4885POLB 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.